In the "12+12" arm of PROVE-3, the % with undetectable virus at 12 weeks (end of Telaprevir portion of treatment) was 75% (86/115), and the % with undetectable virus at 24 weeks (end of all treatment) was 70% (80/115 or 81/115). (These numbers were reported in June 2008: #msg-29896176). Thus, 5 or 6 of the 86 patients in question had a viral breakthrough while on the SoC portion of the regimen.
Corresponding data for the "24+24" arm have not been disclosed.
Market Data 
Markets 
AI
